Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
1(17%)
Results Posted
50%(1 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_1
3
50%
Ph phase_2
3
50%

Phase Distribution

3

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
3(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(2)
Terminated(2)
Other(1)

Detailed Status

Completed2
Recruiting1
Terminated1
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (50.0%)
Phase 23 (50.0%)

Trials by Status

completed233%
recruiting117%
terminated117%
unknown117%
withdrawn117%

Recent Activity

1 active trials
Showing 5 of 6
terminatedphase_2

A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors

NCT04260256
completedphase_1

Detection of Graft Versus Host Disease With [18F]F-AraG

NCT03367962
recruitingphase_2

Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG

NCT06107374
unknownphase_1

[18F]FAraG PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy and/or Radiation Therapy

NCT03142204
withdrawnphase_2

T-Cell PET Imaging With [18F]F-AraG in Lung Cancer

NCT03311672
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04260256Phase 2

A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors

Terminated
NCT03367962Phase 1

Detection of Graft Versus Host Disease With [18F]F-AraG

Completed
NCT06107374Phase 2

Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG

Recruiting
NCT03142204Phase 1

[18F]FAraG PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy and/or Radiation Therapy

Unknown
NCT03311672Phase 2

T-Cell PET Imaging With [18F]F-AraG in Lung Cancer

Withdrawn
NCT02323893Phase 1

Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6